促红细胞生成素治疗透析前贫血临床分析

Clinical analysis of therapy for anemia before hemodialysis with erythropoietin

目的 观察人类重组红细胞生成素 (r -HuEPO)对透析前贫血的疗效 ,探讨早期治疗肾性贫血的意义。方法 患者分两组 ,治疗组应用r-HuEPO皮下注射 ,补充叶酸、铁剂 ,给予饮食疗法、大黄散、控制血压等措施。对照组不用r -HuEPO治疗 ,其它措施相同。观察症状、HGB、HCT、SCr和血清钾、钠、氯水平。结果 治疗组症状改善 ,生活质量提高 ;HGB、HCT明显升高 ,与对照组比较有显著性差异 (P <0 .0 1)。血清肌酐无明显升高。结论 r-HuEPO能明显提高HGB、HCT水平 ,安全有效治疗透析前贫血 ,肾性贫血早期治疗值得重视和进一步探讨。

Objective:To investigate the significance of the early therapy renalanemia before hemodialysis with recombinant human erythropoietin(r-HuEPO).Methods:Patients were divided into two groups. In therapy group treated withr-HuEPO by subcutaneous, folic acid, iron, sitotherapy, Da'huang decoction andcontrol blood pressure. In control group treated with the same except withoutr-HuEPO. Observed the change of symptom, Hemoglobin(HGB), Hematocrit(HCT),Serum Creatinine(SCr) and the level of serum K+,Na+,Cl-.Results:In therapy group The symptom was improved, the living quality was better, HGB and HCT were significantly higher than before, There was significantly difference contrast to control group(P<0.01). SCr were not increased significantly.Conclusions: r-HuEPO can improve the level of HGB and HCT, with safe and efficacious treatment to anemia before hemodialysis. The early therapy of renal anemia is valuable to be attentived and further study.